Skip to content
Biodatica
Start free

North Eastern German Society of Gynaecological Oncology

Innsbruck

OncologyFiled/Approved
Compare Sign in to watch

What changed

Phase II trial registered: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

5mo agoTrial registeredFeb 12, 2026Source filing (opens the source filing in a new tab)

Momentum

64no change

Momentum 64 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

45 pre-ticker oncology companies at Filed/Approved

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Oct 11, 2024

    Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma · RECRUITING · sponsor: North Eastern German Society of Gynaecological Oncology · A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

    ClinicalTrials.gov · NCT05460000 (opens the source filing in a new tab)

  2. Trial

    PHASE4 registered

    Feb 1, 2018

    Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma · TERMINATED · sponsor: North Eastern German Society of Gynaecological Oncology · QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

    ClinicalTrials.gov · NCT03164980 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources